IL-6 and downstream JAK-dependent signaling pathways have critical roles in the pathophysiology of multiple myeloma (MM). We investigated the effects of a novel small-molecule JAK inhibitor ...

Furthermore, an Investigational New Drug (IND) application is expected for BP1003, a liposome-incorporated STAT3 antisense oligodeoxynucleotide developed as a STAT3 inhibitor.

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer ...